Alterity Therapeutics Ltd. filings document a foreign private issuer and development-stage biotechnology company focused on disease-modifying treatments for neurodegenerative diseases. Its Form 6-K reports provide current updates on the company’s Multiple System Atrophy program, including ATH434, the bioMUSE Natural History Study, quantitative MRI biomarker research, medical meeting presentations, and clinical or regulatory program activity.
The filing record also includes Appendix 4C quarterly cash-flow and corporate activity reports, exhibits incorporated by reference into Form S-8 and Form F-3 registration statements, governance updates, and notices related to securities matters such as consolidation or split activity. These filings describe the company’s operating progress, financing framework, board and management disclosures, risk-related development context, and capital-structure records.
Alterity Therapeutics Limited, a development-stage enterprise based in Melbourne, submitted a Form 6-K as a foreign private issuer. The filing is incorporated by reference into several existing Form S-8 and Form F-3 registration statements.
Through an attached Appendix 3X, Alterity reports the appointment of Ann Cunningham as a director effective 17 April 2026. The notice states that she currently has no relevant interests in Alterity securities as a registered holder.
Alterity Therapeutics Limited has appointed Ms Ann Cunningham as an independent Non-Executive Director to its Board, effective 17 April 2026. She brings more than 25 years of global pharmaceutical and biotechnology experience, with deep expertise in commercial strategy across neurodegenerative disease and psychiatry.
Cunningham has held senior roles at Eli Lilly and Teva Pharmaceuticals, leading marketing and sales teams and overseeing neurodegenerative and psychiatry portfolios. Her appointment comes as Alterity prepares to advance its lead asset ATH434 into Phase 3 development for Multiple System Atrophy and move toward potential commercialisation.
Alterity Therapeutics Limited filed a Form 6-K highlighting a scientific milestone for its lead drug candidate ATH434. Daniel Claassen, M.D., Professor of Neurology at Vanderbilt University Medical Center and Chief Medical Advisor for Alterity, will present late-breaking clinical data at the American Academy of Neurology Annual Meeting in Chicago.
The oral presentation, titled “ATH434 Demonstrates Disease-Modifying Signal in Multiple System Atrophy Using the MuSyCA Composite Scale,” is scheduled for Tuesday, April 21, 2026 at 6:21 PM. ATH434 has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in Multiple System Atrophy and additional positive data in an open-label Phase 2 trial in advanced disease.
Alterity is a clinical stage biotechnology company focused on disease-modifying therapies for Multiple System Atrophy and related Parkinsonian disorders, and is preparing to initiate a Phase 3 pivotal trial in MSA. The company also maintains a broader discovery platform targeting underlying pathology in neurodegenerative diseases.
Alterity Therapeutics Ltd Chief Executive Officer David Allen Stamler filed an initial Form 3 showing his equity holdings in the company. He reports direct ownership of 11,688,312 ordinary shares and indirect ownership of 139,258 American Depositary Shares through HSBC Custody Nominees (Australia) Limited. He also holds several option grants over ordinary shares with exercise prices ranging from $0.0030 to $0.0280 and expirations between August 2026 and August 2030, indicating a sizable long-term equity position.
Alterity Therapeutics is hosting a virtual key opinion leader webcast to discuss ATH434 for treating Multiple System Atrophy (MSA), a rare, rapidly progressive neurodegenerative disease with no approved treatment. The event will feature neurologists Roy Freeman, MD, and Daniel Claassen, MD, MS, alongside CEO David Stamler, MD.
The company describes ATH434 as its lead asset and notes that it has shown clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 trial in MSA, with additional positive data from an open label Phase 2 study in advanced MSA. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA and continues to develop a broader drug discovery platform targeting the underlying pathology of neurodegenerative diseases.
ALTERITY THERAPEUTICS LTD director Lawrence Bernard Gozlan has filed an initial Form 3 showing his indirect holdings in the company. The filing reports 4,545,455 ordinary shares held indirectly through Montoya Pty Ltd <Buttercup A/C>.
He also indirectly holds listed options over 1,515,152 ordinary shares with a conversion price of $0.028 per share, expiring on 26 February 2027, and unlisted options over 50,000,000 ordinary shares with a conversion price of $0.010 per share, expiring on 30 December 2027. The Form 3 records these positions as existing holdings rather than new market purchases or sales.
ALTERITY THERAPEUTICS LTD director Julian Michael Babarczy filed an initial Form 3, which is a required disclosure of insider holdings. The filing lists him as a director but shows no reportable transactions, exercises, gifts, or restructurings and no derivative positions in this snapshot.
Alterity Therapeutics director Peter Ashley Marks filed an initial Form 3 reporting his beneficial holdings in the company. He indirectly holds 1,818,182 Ordinary shares through Shanti Capital Pty Ltd <Peter Marks Super Fund A/C>. He also holds listed options over 606,061 Ordinary shares with a conversion price of $0.028 per share expiring on 26 Feb 2027, and unlisted options over 30,000,000 Ordinary shares with a conversion price of $0.010 per share expiring on 30 Dec 2027.